about
Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryPractical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder SyndromeImpact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology.Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms.Body mass index and age are predictors for symptom improvement after high-power laser vaporization for benign prostatic hyperplasia.Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.Optimizing a Male Reproductive Aging Mouse Model by D-Galactose Injection.Chronic Prostatitis/Chronic Pelvic Pain Syndrome is associated with Irritable Bowel Syndrome: A Population-based Study.Neuroprotective effect of docosahexaenoic acid nanoemulsion on erectile function in a rat model of bilateral cavernous nerve injury.High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Current and potential urological applications of botulinum toxin A.Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From MedicationDifferent number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms.Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model.Role of Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy: A Video-urodynamic Analysis.Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.Androgens inhibit tumor necrosis factor-α-induced cell adhesion and promote tube formation of human coronary artery endothelial cells.Restoration of erectile function with intracavernous injections of endothelial progenitor cells after bilateral cavernous nerve injury in ratsRe: Outcome of surgery for primary hyperaldosternonismChange in intraoperative rectal temperature influencing erectile dysfunction following transurethral resection of the prostateHow to choose first-line treatment for men with predominant storage lower urinary tract symptoms: a prospective randomised comparative studyBody mass index and buttock circumference are independent predictors of disintegration failure in extracorporeal shock wave lithotripsy for ureteral calculi
P50
Q26749608-6579F3C9-9EEB-464E-9D5A-A30B8DEB85BDQ26770415-D0C3BCF0-6DC1-4763-A4B9-0E7F4A451F9CQ30315523-52EF6630-C59A-4F58-B590-A88F6EDD5BA0Q34078888-C3B07CB1-E91A-41AA-912E-929615108717Q34634768-6A7213A3-1BE8-435D-939A-821934C3CB9DQ35578945-5B9CE47B-CD8A-406D-9E81-7C8B28597593Q36090770-0D5023B9-AB51-43E4-884B-4C75DE1FF003Q36512614-BD1C2D59-F478-419D-9112-41FB57ABCC20Q36937474-90911417-FAF4-4C27-84FD-8909F240D1A3Q37254286-13B75E36-A5A7-4E93-8103-21AA3C31F808Q37409521-280F7B3F-1EA8-48C8-B77E-00B38758F5A7Q38564108-AAE2E9AA-232C-466A-8822-49EC677875BBQ39422921-12269735-CE4F-4212-8438-E65458696D75Q40636667-B2DCB683-0E48-40E3-8257-C27B4373EA58Q41284362-944BDBE6-B854-4344-8158-3F560CF24CD8Q43479365-8D6A9F37-C435-43B4-BB1D-932F24CE9051Q44754205-F3D77EC4-C648-4852-A9FF-E2295CA13047Q45272540-E22CCE46-2823-4AA4-A00D-0E481FA90296Q48081848-A4EA73EB-3560-408F-B0D3-B9ECF74A3EDDQ48277156-600AD5B2-1CCD-424C-9CF4-46F62C53400AQ51367455-9207A4C0-C249-40F4-9A37-55D7BCFFCACEQ53018072-C0F35199-3BA0-4066-9EC3-5E36E76D70D4Q53096018-C57429E3-6821-4004-8744-517C83E0F6A6Q53098450-64ADBC34-C820-4598-9DCE-12D6267F0F8CQ53174118-4A1BD5A4-9970-4373-9A24-5227D7B30445Q62690245-F38C5D78-532B-461B-9001-4BF4AF47B7EAQ83620616-8397B324-04B4-4C53-96DE-2643AD293692Q84501531-4BCF17FB-A0E3-4D3E-9C8A-A0B6E240207DQ86246868-04DB2E2A-F875-4D17-94B0-A8184779F51BQ87222599-341586D6-B647-4CDB-B299-893142770C64
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chun-Hou Liao
@ast
Chun-Hou Liao
@en
Chun-Hou Liao
@es
Chun-Hou Liao
@sl
type
label
Chun-Hou Liao
@ast
Chun-Hou Liao
@en
Chun-Hou Liao
@es
Chun-Hou Liao
@sl
prefLabel
Chun-Hou Liao
@ast
Chun-Hou Liao
@en
Chun-Hou Liao
@es
Chun-Hou Liao
@sl
P106
P31
P496
0000-0002-7340-110X